Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Heat shock proteins (HSPs) are key molecular chaperones that confer resistance to various cellular stresses in cancer cells.
• HSP90, HSP70, and HSP27 are critical HSPs that support cancer cell survival and can impede the efficacy of conventional anti-cancer treatments.

Purpose of the Study:

• To review the therapeutic potential of inhibiting heat shock response pathways, focusing on HSP90, HSP70, and HSP27.
• To evaluate the combination strategies of HSP inhibitors with existing anti-cancer therapies.

Main Methods:

• Literature review of studies investigating HSP inhibitors as monotherapy or in combination with anti-cancer agents.
• Analysis of data on the impact of co-administering chaperone inhibitors and targeting drugs on tumor cell physiology.

Main Results:

• Inhibitors targeting HSP90, HSP70, and HSP27 show promise in sensitizing cancer cells to therapy.
• Co-administration of HSP inhibitors with anti-cancer drugs induces significant proteotoxic stress, disrupting tumor cell homeostasis.
• Combination therapies can overcome resistance mechanisms mediated by HSPs.

Conclusions:

• Targeting the heat shock response, particularly HSP90, HSP70, and HSP27, is a viable strategy to enhance anti-cancer therapies.
• Optimal drug combinations should aim to simultaneously inhibit cytoprotective HSP mechanisms and induce critical imbalances in tumor cell physiology.
• The combination of HSP inhibitors with conventional anti-cancer treatments offers a promising approach to improve therapeutic outcomes in oncology.